Osteocytes in normal physiology and osteoporosis

Clinical Reviews in Bone and Mineral Metabolism

Volumn 8, Issue 4, 2010, Pages 224-232

  Watanabe, Ken ^a   Ikeda, Kyoji ^a  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Aging; Cell fate; Extracellular matrix; Gene expression; Human disease; Mechanical signal; Mineralization; Mouse genetics; Osteoblast; Osteoclast; PTH; Wnt signaling

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 8 APLHA; COLLAGEN; COLLAGEN TYPE 1; DENTIN MATRIX PROTEIN 1; DICKKOPF 1 PROTEIN; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 23; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PERLECAN; PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; PODOPLANIN; PROTEIN ENPP 1; PROTEOGLYCAN; SCLEROSTIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR DLX 3; TRANSCRIPTION FACTOR IRX 5; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR TCF 7; TRANSCRIPTION FACTOR VDR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AUTOSOMAL DOMINANT HYPOPHOSPHATEMIC RICKETS; BIOSYNTHESIS; BONE AGE; BONE MASS; BONE MINERALIZATION; CALCIUM BLOOD LEVEL; CELL DIFFERENTIATION; CELL FATE; CELL FUNCTION; CELL LINE; CELL STRUCTURE; DENDRITE; DISEASE SEVERITY; GAP JUNCTION; GENE EXPRESSION; HUMAN; HYPOPHOSPHATEMIA; LOSS OF FUNCTION MUTATION; MECHANOTRANSDUCTION; METABOLIC DISORDER; METABOLIC REGULATION; MINERAL METABOLISM; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; OSTEOMALACIA; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHENOTYPE; PHOSPHATE METABOLISM; PHYSIOLOGY; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; SCHWARTZ JAMPEL SYNDROME; SIGNAL TRANSDUCTION;

EID: 79960115933     PISSN: 15348644     EISSN: 15590119     Source Type: Journal    
DOI: 10.1007/s12018-010-9076-0     Document Type: Review

References (103)

1. Nijweide PJ, Burger EH, Klein-Nulend J. The osteocyte. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of bone biology. 2nd ed. San Diego: Academic Press; 2002. p. 93-107.
2. Bonewald LF, Johnson ML. Osteocytes, mechanosensing and Wnt signaling. Bone. 2008;42:606-15.
3. Noble BS. The osteocyte lineage. Arch Biochem Biophys. 2008;473:106-11.
4. Burger EH, Klein-Nulend J. Mechanotransduction in bone-role of the lacuno-canalicular network. FASEB J. 1999;13(Suppl): S101-12.
5. Dean AK, Harris SE, Kalajzic I, Ruan J. A systems biology approach to the identification and analysis of transcriptional regulatory networks in osteocytes. BMC Bioinformatics. 2009;10(Suppl 9):S5.
6. Paic F, Igwe JC, Nori R, Kronenberg MS, Franceschetti T, Harrington P, Kuo L, Shin DG, Rowe DW, Harris SE, Kalajzic I. Identification of differentially expressed genes between osteoblasts and osteocytes. Bone. 2009;45:682-92.
7. Franz-Odendaal TA, Hall BK, Witten PE. Buried alive: How osteoblasts become osteocytes. Dev Dyn. 2006;235: 176-90. (Pubitemid 46939715)
8. Kalajzic I, Braut A, Guo D, Jiang X, Kronenberg MS, Mina M, Harris MA, Harris SE, Rowe DW. Dentin matrix protein 1 expression during osteoblastic differentiation, generation of an osteocyte GFP-transgene. Bone. 2004;35:74-82. (Pubitemid 38789150)
9. Wetterwald A, Hoffstetter W, Cecchini MG, Lanske B, Wagner C, Fleisch H, Atkinson M. Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes. Bone. 1996;18:125-32. (Pubitemid 26092592)
10. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling- Hampton K, Appleby M, Brunkow ME, Latham JA. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003;22:6267-76. (Pubitemid 37522584)
11. Kobayashi K, Imanishi Y, Koshiyama H, Miyauchi A, Wakasa K, Kawata T, Goto H, Ohashi H, Koyano HM, Mochizuki R, Miki T, Inaba M, Nishizawa Y. Expression of FGF23 is correlated with serum phosphate level in isolated fibrous dysplasia. Life Sci. 2006;78:2295-301.
12. Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab. 2006;291:E38-49. (Pubitemid 44035308)
13. Yang W, Harris MA, Heinrich JG, Guo D, Bonewald LF, Harris SE. Gene expression signatures of a fibroblastoid preosteoblast and cuboidal osteoblast cell model compared to the MLO-Y4 osteocyte cell model. Bone. 2009;44:32-45.
14. Li H, Marijanovic I, Kronenberg MS, Erceg I, Stover ML, Velonis D, Mina M, Heinrich JG, Harris SE, Upholt WB, Kalajzic I, Lichtler AC. Expression and function of Dlx genes in the osteoblast lineage. Dev Biol. 2008;316:458-70.
15. Leupin O, Kramer I, Collette NM, Loots GG, Natt F, Kneissel M, Keller H. Control of the SOST bone enhancer by PTH usingMEF2 transcription factors. J Bone Miner Res. 2007;22:1957-67. (Pubitemid 351229312)
16. Zhou X, Zhang Z, Feng JQ, Dusevich VM, Sinha K, Zhang H, Darnay BG, de Crombrugghe B. Multiple functions of Osterix are required for bone growth and homeostasis in postnatal mice. Proc Natl Acad Sci USA. 2010;107:12919-24.
17. Hwang J, Mehrani T, Millar SE, Morasso MI. Dlx3 is a crucial regulator of hair follicle differentiation and cycling. Development. 2008;135:3149-59.
18. Willert K, Jones KA. Wnt signaling: Is the party in the nucleus? Genes Dev. 2006;20:1394-404. (Pubitemid 43830647)
19. Zhang C, Cho K, Huang Y, Lyons JP, Zhou X, Sinha K, McCrea PD, de Crombrugghe B. Inhibition of Wnt signaling by the osteoblast-specific transcription factor Osterix. Proc Natl Acad Sci USA. 2008;105:6936-41. (Pubitemid 351754508)
20. Hirao M, Hashimoto J, Yamasaki N, Ando W, Tsuboi H, Myoui A, Yoshikawa H. Oxygen tension is an important mediator of the transformation of osteoblasts to osteocytes. J Bone Miner Metab. 2007;25:266-76. (Pubitemid 47283266)
21. Boukhechba F, Balaguer T, Michiels JF, Ackermann K, Quincey D, Bouler JM, Pyerin W, Carle GF, Rochet N. Human primary osteocyte differentiation in a 3D culture system. J Bone Miner Res. 2009;24:1927-35.
22. Turner CH, Robling AG, Duncan RL, Burr DB. Do bone cells behave like a neuronal network? Calcif Tissue Int. 2002;70: 435-42. (Pubitemid 36929579)
23. Kusuzaki K, Kageyama N, Shinjo H, Takeshita H, Murata H, Hashiguchi S, Ashihara T, Hirasawa Y. Development of bone canaliculi during bone repair. Bone. 2000;27:655-9.
24. Hirose S, Li M, Kojima T, de Freitas PH, Ubaidus S, Oda K, Saito C, Amizuka N. A histological assessment on the distribution of the osteocytic lacunar canalicular system using silver staining. J Bone Miner Metab. 2007;25:374-82. (Pubitemid 350043693)
25. Holmbeck K, Bianco P, Pidoux I, Inoue S, Billinghurst RC, Wu W, Chrysovergis K, Yamada S, Birkedal-Hansen H, Poole AR. The metalloproteinase MT1-MMP is required for normal development and maintenance of osteocyte processes in bone. J Cell Sci. 2005;118:147-56. (Pubitemid 40277113)
26. Schoen FA. A method to stain decalcified bone without loss of structural detail. Biotech Histochem. 1991;66:216-9.
27. Kamioka H, Honjo T, Takano-Yamamoto T. A three-dimensional distribution of osteocyte processes revealed by the combination of confocal laser scanning microscopy and differential interference contrast microscopy. Bone. 2001;28:145-9. (Pubitemid 32140970)
28. Martignetti JA, Aqeel AA, Sewairi WA, Boumah CE, Kambouris M, Mayouf SA, Sheth KV, EidWA,DowlingO, Harris J, Glucksman MJ, Bahabri S, Meyer BF, Desnick RJ. Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. Nat Genet. 2001;28:261-5. (Pubitemid 32626029)
29. Inoue K, Mikuni-Takagaki Y, Oikawa K, Itoh T, Inada M, Noguchi T, Park JS, Onodera T, Krane SM, Noda M, Itohara S. A crucial role for matrix metalloproteinase 2 in osteocytic canalicular formation and bone metabolism. J Biol Chem. 2006;281:33814-24. (Pubitemid 46036758)
30. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006;38:1310-5. (Pubitemid 44646294)
31. You LD, Weinbaum S, Cowin SC, Schaffler MB. Ultrastructure of the osteocyte process and its pericellular matrix. Anat Rec A Discov Mol Cell Evol Biol. 2004;278:505-13. (Pubitemid 38724147)
32. Sauren YM, Mieremet RH, Groot CG, Scherft JP. An electron microscopic study on the presence of proteoglycans in the mineralized matrix of rat and human compact lamellar bone. Anat Rec. 1992;232:36-44.
33. Burra S, Nicolella DP, Francis WL, Freitas CJ, Mueschke NJ, Poole K, Jiang JX. Dendritic processes of osteocytes are mechanotransducers that induce the opening of hemichannels. Proc Natl Acad Sci USA. 2010;107:13648-53.
34. Wang L, Wang Y, Han Y, Henderson SC, Majeska RJ, Weinbaum S, Schaffler MB. In situ measurement of solute transport in the bone lacunar-canalicular system. Proc Natl Acad Sci USA. 2005;102:11911-6. (Pubitemid 41170824)
35. Cowin SC, Weinbaum S, Zeng Y. A case for bone canaliculi as the anatomical site of strain generated potentials. J Biomech. 1995;28:1281-97.
36. Forsberg E, Kjellen L. Heparan sulfate: Lessons from knockout mice. J Clin Invest. 2001;108:175-80. (Pubitemid 32656239)
37. Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature. 2007;446:1030-7. (Pubitemid 46676065)
38. Arikawa-Hirasawa E, Watanabe H, Takami H, Hassell JR, Yamada Y. Perlecan is essential for cartilage and cephalic development. Nat Genet. 1999;23:354-8. (Pubitemid 29526437)
39. Rodgers KD, Sasaki T, Aszodi A, Jacenko O. Reduced perlecan in mice results in chondrodysplasia resembling Schwartz-Jampel syndrome. Hum Mol Genet. 2007;16:515-28. (Pubitemid 46522614)
40. Nicole S, Davoine CS, Topaloglu H, Cattolico L, Barral D, Beighton P, Hamida CB, Hammouda H, Cruaud C, White PS, Samson D, Urtizberea JA, Lehmann-Horn F, Weissenbach J, Hentati F, Fontaine B. Perlecan, the major proteoglycan of basement membranes, is altered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia). Nat Genet. 2000;26:480-3.
41. Thompson WR, Modla S, Grindel BJ, Czymmek KJ, Kirn- Safran CB, Wang L, Duncan RL, Farach-Carson MC. Perlecan/ Hspg2 deficiency alters the pericellular space of the lacunocanalicular system surrounding osteocytic processes in cortical bone. J Bone Miner Res. 2010.
42. Fukumoto S. The role of bone in phosphate metabolism. Mol Cell Endocrinol. 2009;310:63-70.
43. Bonewald LF. Osteocytes as dynamic multifunctional cells. Ann NY Acad Sci. 2007;1116:281-90. (Pubitemid 350274320)
44. Francis F, Hennig S, Korn B, Reinhardt R, de Jong P, Poustka A, Lehrach H, Rowe PSN, Goulding JN, Summerfield T, Mountford R, Read AP, Popowska E, Pronicka E, Davies KE, O'Riordan JLH, Econs MJ, Nesbitt T, Drezner MK, Oudet CL, Pannetier S, Hanauer A, Strom TM, Meindl A, Lorenz B, Cagnoli B, Mohnike KL, Murken J, Meitinger T. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet. 1995;11:130-6.
45. Yuan B, Takaiwa M, Clemens TL, Feng JQ, Kumar R, Rowe PS, Xie Y, Drezner MK. Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest. 2008;118:722-34. (Pubitemid 351206560)
46. Fukumoto S. Actions and mode of actions of FGF19 subfamily members. Endocr J. 2008;55:23-31. (Pubitemid 351520176)
47. Kharitonenkov A. FGFs and metabolism. Curr Opin Pharmacol. 2009;9:805-10.
48. ADHR-Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000;26:345-8.
49. Rowe PS. The wrickkened pathways of FGF23, MEPE and PHEX. Crit Rev Oral Biol Med. 2004;15:264-81. (Pubitemid 44560775)
50. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45-51. (Pubitemid 27494749)
51. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444:770-4. (Pubitemid 44949607)
52. Razzaque MS, Lanske B. Hypervitaminosis D and premature aging: Lessons learned from Fgf23 and Klotho mutant mice. Trends Mol Med. 2006;12:298-305. (Pubitemid 44110001)
53. Lorenz-Depiereux B, Bastepe M, Benet-Pages A, Amyere M, Wagenstaller J, Muller-Barth U, Badenhoop K, Kaiser SM, Rittmaster RS, Shlossberg AH, Olivares JL, Loris C, Ramos FJ, Glorieux F, Vikkula M, Juppner H, Strom TM. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet. 2006;38:1248-50. (Pubitemid 44646286)
54. Miller WL, Portale AA. Genetic causes of rickets. Curr Opin Pediatr. 1999;11:333-9. (Pubitemid 29406507)
55. Rowe PS, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ, Oudet CL. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics. 2000;67:54-68. (Pubitemid 30471121)
56. Petersen DN, Tkalcevic GT, Mansolf AL, Rivera-Gonzalez R, Brown TA. Identification of osteoblast/osteocyte factor 45 (OF45), a bone-specific cDNA encoding an RGD-containing protein that is highly expressed in osteoblasts and osteocytes. J Biol Chem. 2000;275:36172-80.
57. Gowen LC, Petersen DN, Mansolf AL, Qi H, Stock JL, Tkalcevic GT, Simmons HA, Crawford DT, Chidsey-Frink KL, Ke HZ, McNeish JD, Brown TA. Targeted disruption of the osteoblast/ osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem. 2003;278:1998-2007. (Pubitemid 36801442)
58. Fisher LW, Fedarko NS. Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res. 2003;44(Suppl 1):33-40. (Pubitemid 36395419)
59. Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun. 2001;280:460-5. (Pubitemid 32912812)
60. Bellahcene A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): Multifunctional proteins in cancer. Nat Rev Cancer. 2008;8:212-26. (Pubitemid 351301854)
61. Rowe PS, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D, Cundy J, Navvab S, Chen D, Drezner MK, Quarles LD, Mundy GR. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone. 2004;34:303-19. (Pubitemid 38177612)
62. Lorenz-Depiereux B, Schnabel D, Tiosano D, Hausler G, Strom TM. Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet. 2010;86:267-72.
63. Levy-Litan V, Hershkovitz E, Avizov L, Leventhal N, Bercovich D, Chalifa-Caspi V, Manor E, Buriakovsky S, Hadad Y, Goding J, Parvari R. Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet. 2010;86:273-8.
64. Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R, Millan JL. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: An integrated model of the pathogenesis of mineralization disorders. Am J Pathol. 2004;164:1199-209. (Pubitemid 38387787)
65. Rutsch F, Ruf N, Vaingankar S, Toliat MR, Suk A, Hohne W, Schauer G, Lehmann M, Roscioli T, Schnabel D, Epplen JT, Knisely A, Superti-Furga A, McGill J, Filippone M, Sinaiko AR, Vallance H, Hinrichs B, Smith W, Ferre M, Terkeltaub R, Nurnberg P. Mutations in ENPP1 are associated with'idiopathic' infantile arterial calcification. Nat Genet. 2003;34:379-81. (Pubitemid 36935330)
66. Okawa A, Nakamura I, Goto S, Moriya H, Nakamura Y, Ikegawa S. Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet. 1998;19:271-3. (Pubitemid 28309341)
67. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113:561-8. (Pubitemid 38542505)
68. Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, Juppner H, Lanske B. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 2004;23:421-32. (Pubitemid 39576657)
69. Aono Y, Yamazaki Y, Yasutake J, Kawata T, Hasegawa H, Urakawa I, Fujita T, Wada M, Yamashita T, Fukumoto S, Shimada T. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res. 2009;24:1879-88.
70. Tashjian AH Jr, Gagel RF. Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res. 2006;21:354-65.
71. Canalis E. Update in new anabolic therapies for osteoporosis. J Clin Endocrinol Metab. 2010;95:1496-504.
72. O'Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, Robling AG, Bouxsein M, Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC, Bellido T. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One. 2008;3:e2942.
73. Guo J, Liu M, Yang D, Bouxsein ML, Saito H, Galvin RJ, Kuhstoss SA, Thomas CC, Schipani E, Baron R, Bringhurst FR, Kronenberg HM. Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. Cell Metab. 2010;11:161-71.
74. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005;146:4577-83. (Pubitemid 41446595)
75. Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone. 2005;37:148-58. (Pubitemid 40962421)
76. Wan M, Yang C, Li J, Wu X, Yuan H, Ma H, He X, Nie S, Chang C, Cao X. Parathyroid hormone signaling through lowdensity lipoprotein-related protein 6. Genes Dev. 2008;22: 2968-79.
77. Kulkarni NH, Halladay DL, Miles RR, Gilbert LM, Frolik CA, Galvin RJ, Martin TJ, Gillespie MT, Onyia JE. Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem. 2005;95:1178-90. (Pubitemid 41420125)
78. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA. 1999; 96:5522-7. (Pubitemid 29234650)
79. Glass DA II, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8:751-64. (Pubitemid 40585297)
80. Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, Bouxsein ML, Deng L, Clemens TL, Williams BO. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem. 2005;280:21162-8. (Pubitemid 40805677)
81. Kramer I, Halleux C, Keller H, Pegurri M, Gooi JH, Weber PB, Feng JQ, Bonewald LF, Kneissel M. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol. 2010;30:3071-85.
82. Fu Q, Jilka RL, Manolagas SC, O'Brien CA. Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem. 2002;277:48868-75. (Pubitemid 35470855)
83. Kondo H, Guo J, Bringhurst FR. Cyclic adenosine monophosphate/ protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. J Bone Miner Res. 2002;17:1667-79.
84. Lee SK, Lorenzo JA. Regulation of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow cultures. Bone. 2002;31:252-9. (Pubitemid 34754455)
85. Qing H, Bonewald LF. Osteocyte remodeling of the perilacunar and pericanalicular matrix. Int J Oral Sci. 2009;1:59-65.
86. Teti A, Zallone A. Do osteocytes contribute to bone mineral homeostasis? Osteocytic osteolysis revisited. Bone. 2009;44: 11-6.
87. Talmage RV, Grubb SA. A laboratory model demonstrating osteocyte-osteoblast control of plasma calcium concentrations. Table model for plasma calcium control. Clin Orthop Relat Res. 1977;122:299-306.
88. Krempien B, Friedrich E, Ritz E. Effect of PTH on osteocyte ultrastructure. Adv Exp Med Biol. 1978;103:437-50.
89. Tazawa K, Hoshi K, Kawamoto S, Tanaka M, Ejiri S, Ozawa H. Osteocytic osteolysis observed in rats to which parathyroid hormone was continuously administered. J Bone Miner Metab. 2004;22:524-9. (Pubitemid 39517871)
90. Noble BS, Peet N, Stevens HY, Brabbs A, Mosley JR, Reilly GC, Reeve J, Skerry TM, Lanyon LE. Mechanical loading: Biphasic osteocyte survival and targeting of osteoclasts for bone destruction in rat cortical bone. Am J Physiol Cell Physiol. 2003;284:C934-43. (Pubitemid 36336949)
91. Verborgt O, Gibson GJ, Schaffler MB. Loss of osteocyte integrity in association with microdamage and bone remodeling after fatigue in vivo. J Bone Miner Res. 2000;15:60-7. (Pubitemid 30026933)
92. Tatsumi S, Ishii K, Amizuka N, Li M, Kobayashi T, Kohno K, Ito M, Takeshita S, Ikeda K. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab. 2007;5:464-75. (Pubitemid 46825494)
93. Hazenberg JG, Freeley M, Foran E, Lee TC, Taylor D. Microdamage: A cell transducing mechanism based on ruptured osteocyte processes. J Biomech. 2006;39:2096-103. (Pubitemid 44038721)
94. Noble B. Bone microdamage and cell apoptosis. Eur Cell Mater. 2003;6:46-55. discussion 55. (Pubitemid 38851420)
95. Tomkinson A, Gevers EF, Wit JM, Reeve J, Noble BS. The role of estrogen in the control of rat osteocyte apoptosis. J Bone Miner Res. 1998;13:1243-50. (Pubitemid 28373325)
96. Vashishth D, Verborgt O, Divine G, Schaffler MB, Fyhrie DP. Decline in osteocyte lacunar density in human cortical bone is associated with accumulation of microcracks with age. Bone. 2000;26:375-80. (Pubitemid 30136128)
97. Qiu S, Rao DS, Palnitkar S, Parfitt AM. Reduced iliac cancellous osteocyte density in patients with osteoporotic vertebral fracture. J Bone Miner Res. 2003;18:1657-63. (Pubitemid 37022924)
98. Qiu S, Rao DS, Palnitkar S, Parfitt AM. Age and distance from the surface but not menopause reduce osteocyte density in human cancellous bone. Bone. 2002;31:313-8. (Pubitemid 34822826)
99. Abu EO, Horner A, Kusec V, Triffitt JT, Compston JE. The localization of the functional glucocorticoid receptor alpha in human bone. J Clin Endocrinol Metab. 2000;85:883-9. (Pubitemid 32273683)
100. Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab. 2000;85:2907-12. (Pubitemid 32269172)
101. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102:274-82. (Pubitemid 28335186)
102. Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem. 2005;280: 7317-25. (Pubitemid 40341290)
103. Roelofs AJ, Coxon FP, Ebetino FH, Lundy MW, Henneman ZJ, Nancollas GH, Sun S, Blazewska KM, Bala JL, Kashemirov BA, Khalid AB, McKenna CE, Rogers MJ. Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res. 2010;25:606-16.